Document:

Exhibit

EMPLOYMENT AGREEMENT
between

L. Kellenberger & Co. AG, Heiligkreuzstrasse 28, 9008 St. Gallen
(hereinafter referred to as the "Company")

and

Urs Baumgartner, Sommerauweg 8, CH-8555 Mühlheim-Dorf
(hereinafter referred to as the "Employee")

WHEREAS, the Company desires to continue to employ the Employee to provide services pursuant to the terms of this Agreement;
NOW THEREFORE, in consideration of the covenants and agreements hereinafter set forth, the parties hereto agree as follows:

1.     EMPLOYMENT AND DUTIES

1.1. General.   The Company hereby continues to employ the Employee, and the Employee agrees to serve, as Chief Executive Officer of the Company, upon the terms and conditions herein contained.
The Employee shall perform such duties and services for the Company as may be designated from time to time by the Chairman of the Board of the Company. The Employee agrees to serve the Company faithfully and to the best of his ability under the direction of the Board of Directors of the Company (the “Board”) or the Chief Executive Officer of Hardinge Inc., the parent corporation of the Company (the “Parent”).

1.2. Exclusive Services.   Except as may otherwise be approved in advance by the Managing Director, and except during vacation periods and reasonable periods of absence due to sickness, personal injury or other disability, the Employee shall devote his full working 

1 -

time throughout the Employment Term (as defined in Section 1.3) to the services required of him hereunder. The Employee shall render his services exclusively to the Company during the Employment Term, and shall use his best efforts, judgment and energy to improve and advance the business and interests of the Company in a manner consistent with the duties of his position.
1.3. Term of Employment.   The employment shall continue for an indefinite period of time. The present agreement came into effect as per August 1st, 2015 and shall be amended as of October 28, 2016. The employment can be terminated subject to twelve months notice as per the end of a calendar month. Reservation is made for Art. 337 CO.  If the Employee’s employment is terminated by the Company within twelve months following a Change in Control (i.e., (i) the sale of all or substantially all of the Company’s assets to any entity of which the Parent does not own, directly or indirectly, at least 85% of the outstanding voting securities; or (ii) the sale or other transfer of more than 50% of the outstanding voting securities to any person or entity other than the Parent or an entity of which the Parent owns, directly or indirectly, at least 50% of the outstanding voting securities ), the employment can be terminated subject to eighteen months notice as per the end of a calendar month.  

1.4 Reimbursement of Expenses.   The Company shall reimburse the Employee for reasonable travel and other business expenses incurred by him in the fulfillment of his duties hereunder upon presentation by the Employee of an itemized account of such expenditures, in accordance with Company practices consistently applied.

2.     ANNUAL COMPENSATION

2.1     Base Salary.   From the date hereof, the Employee shall be entitled to receive a base salary ("Base Salary") at a gross rate of CHF 275'000 per annum payable in accordance with the Company's payroll practices, with such changes as may be provided in accordance with the terms hereof. Once changed, such amount shall constitute the Employee's annual Base Salary.
2.2     Annual Review.  The Employee's Base Salary shall be reviewed by the Managing Director, based upon the Employee's performance, not less often than annually.
2.3     Bonus.  After the date hereof, the Employee shall be entitled to such bonus, if any, as may be awarded to the Employee from time to time by the Board of Directors.
2.4     Company Car.   The Employee shall be entitled to a Company car, in accordance with Company's current policy.

2 -

3.     EMPLOYEE BENEFITS
The Employee shall, during his employment under this Agreement, be included to the extent eligible thereunder in all employee benefit plans, programs or arrangements including, without limitation, any plans, programs or arrangements providing for retirement benefits, incentive compensation, profit sharing, disability benefits, which are compulsory under Swiss law or shall be established by the Company for, or made available to, its employees generally.

4.     WORKING TIME AND HOLIDAYS

4.1     The working time of the Employee shall be commensurate with the task and responsibility and must therefore be adapted by the Employee to the necessities of the business and the proper conduct of the Company's affairs.
421     Any overtime work shall be deemed to be remunerated by the compensation set out in Art. 2 and 3.
4.3     The Employee is entitled to at least 25 working days paid holidays in accordance with Art. 13 of the Collective Employment Contract of the Machine Industry of 1st July 2013, inforce until 31st December 2018. In an uncompleted year of employment, the Employee shall be entitled to holidays ratably in proportion to the time of employment in the respective year of employment.

5.     DEATH, DISABILITY OR RETIREMENT.
In the event of termination of employment by reason of death, permanent disability or retirement, the Employee (or his estate, as applicable) shall be entitled to Base Salary and benefits determined under Section 3 and 4 through the end of the month following the termination. Other benefits shall be determined in accordance with the benefit plans maintained by the Company, and the Company shall have no further obligation hereunder.

6.     NONSOLICITATION; CONFIDENTIALY; NONCOMPETITION

6.1     Nonsolicitation.   For so long as the Employee is employed by the Company, and continuing until two years after the Employee ceases to be an employee of the Company, the Employee shall not, without the prior written consent of the Company, directly or indirectly, as a sole proprietor, member of a partner­ ship, stockholder or investor, officer or director of a corporation, or as an employee, associate, consultant or agent of any person, 

3 -

partnership, corporation or other business organization or entity other than the Company: (x) solicit or endeavor to entice away from the Company or any of its subsidiaries any person or entity who is, or, during the then most recent 12-month period, was employed by, or had served as an agent or key consult­ ant of the Company or any of its subsidiaries; or (y) solicit or endeavor to entice away from the Company or any of its subsidiaries any person or entity who is, or was within the then most recent 12-month period, a customer or client (or reasonably anticipated to the general knowledge of the Employee or the public to become a customer or client) of the Company or any of its subsidiaries.

6.2     Non-competition.   For as long as the Employee is employed by the Company, and continuing for two years after he ceases to be an employee of the Company, the Employee may not compete with the Company in any manner, in particular by 
		
	•
	being active for any person, partnership, corporation or other business organization or entity other than the Company that is in the same business of producing, selling or otherwise providing grinding machines;

		
	•
	alienating, or in the case of the two years after employment, soliciting existing customers of the Company.

The competition prohibition is valid for the entire area in which the Company conducts its business, and in the countries in which the company has been active. In the event of any infringement against the competition prohibition, the Employee owes the Company a contractual penalty equivalent to one half of the most recent total annual compensation paid by the Company to the Employee, without limiting the Company to claim the real damages if the damages suffered by the Company are more important than the Contractual penalty.

6.3     Confidentiality.   The Employee covenants and agrees with the Company that he will not at any time, except in performance of his obligations to the Company hereunder or with the prior written consent of the Company, directly or indirectly, disclose any secret or confidential information that he may learn or has learned by reason of his association with the Company or any of its subsidiaries and affiliates. The term "confidential information" includes information not previously dis­closed to the public or to the trade by the Company's management, or otherwise in the public domain, with respect to the Company's or any of its subsidiaries' or affiliates' products, facilities, applications and methods, trade secrets and other intellectual property, systems, procedures, manuals, confidential reports, product price lists, customer lists, technical in­ formation, financial information (including the revenues, costs of profits associated with any of the Company's products), business plans, prospects or opportunities, but shall exclude any information which (i) is or becomes available to the public or is generally known in the industry or industries in which the Company operates other than as a result of disclosure by the Employee in violation of his agreements under this 

4 -

Section 6.2 or (ii) the Employee is required to disclose under any applicable laws, regulations or directives or any government agency, tribunal or authority having jurisdiction in the matter or under subpoena or other process of law.

6.4     Exclusive Property.   The Employee confirms that all confidential information is and shall remain the exclusive property of the Company. All business records, papers and documents kept or made by Employee relating to the business of the Company shall be and remain the property of the Company.

7.     MISCELLANEOUS

7.1     Severability.   Each provision of this Agreement shall be interpreted in such manner as to be effective and valid under applicable law, but if any provision of this Agreement is held to be prohibited by or invalid under applicable law, such provision will be ineffective only to the extent of such prohibition or invalidity, without invalidating the remainder of such provision or the remaining provisions of this Agreement.
7.2    Assignment.   The rights and obligations of this Agreement shall bind and inure to the benefit of any successor of the Company by reorganization, merger or consolidation, or any assignee of all or substantially all of the Company's business and properties. Neither Agreement nor any rights hereunder shall be assignable.
7.3     Entire Agreement.   This Agreement represents the entire agreement of the parties and shall supersede any and all previous contracts, arrangements or understandings between the Company and the Employee relating to the subject matter hereof. This Agreement may be amended at any time by mutual written agreement of the parties hereto.
7.4     Collective Employment Contract of the Machine Indus try.   The Collective Employment Contract of the Machine Industry of 1st July 2013 will remain in force until 31st December 2018 and is applicable on the Employment with the exception of the provisions contained in this Agreement.
7.5     Internal Regulations of the Company.   The internal regulation enacted 1st January 2015 are integral parts of the Agreement.
7.6     Withholding.   The payment of any amount pursuant to this Agreement shall be subject to applicable withholding and payroll taxes, and such other deductions as may be required under the Company's employee benefit plans, if any.

5 -

7.7     Governing Law.   This Agreement shall be governed by, and construed in accordance with, the laws of Switzerland applicable to contracts executed in and to be performed entirely within Switzerland.

IN WITNESS WHEREOF,     the Company has caused this Agreement to be duly executed and the Employee has hereunto set his hand, as of the day and year fist above written.

Elmira, NY 10/28/2016        /s/ Richard L. Simons___________________
(Place, Date)                 L. Kellenberger & Co. AG

St. Gallen 10/28/2016            /s/ Urs Baumgartner___________________
(Place, Date)                 Urs Baumgartner 

6 -Exhibit 4.7

 

Warrant Certificate
No. PA-50-___

 

NEITHER THE SECURITIES
REPRESENTED BY THIS CERTIFICATE NOR THE SECURITIES ISSUABLE UPON THE EXERCISE OF THIS WARRANT HAVE BEEN REGISTERED UNDER THE SECURITIES
ACT OF 1933, AS AMENDED (THE “ACT”), OR ANY STATE SECURITIES LAWS, AND NEITHER SUCH SECURITIES NOR ANY INTEREST THEREIN
MAY BE OFFERED, SOLD, ASSIGNED OR OTHERWISE TRANSFERRED UNLESS (1) A REGISTRATION STATEMENT WITH RESPECT THERETO IS EFFECTIVE
UNDER THE ACT AND ANY APPLICABLE STATE SECURITIES LAWS, OR (2) AN EXEMPTION FROM SUCH REGISTRATION EXISTS AND THE COMPANY RECEIVES
AN OPINION OF COUNSEL TO THE HOLDER OF SUCH SECURITIES, WHICH COUNSEL AND OPINION ARE SATISFACTORY TO THE COMPANY, THAT SUCH SECURITIES
MAY BE OFFERED, SOLD, PLEDGED, ASSIGNED OR TRANSFERRED IN THE MANNER CONTEMPLATED WITHOUT AN EFFECTIVE REGISTRATION STATEMENT
UNDER THE ACT OR APPLICABLE STATE SECURITIES LAWS.

 

	Effective Date: July 29, 2016	Void After: July 29, 2021

 

MATINAS BIOPHARMA
HOLDINGS, INC.

 

PLACEMENT AGENT
WARRANT

 

Matinas
BioPharma Holdings, Inc., a Delaware corporation (the “Company”), for value received on July 29, 2016 (the
“Effective Date”), hereby issues to ___________ (the “Holder”) this Warrant (the “Warrant”)
to purchase, ________shares (each such share as from time to time adjusted as hereinafter provided being a “Warrant Share”
and all such shares being the “Warrant Shares”) of the Company’s Common Stock (as defined below), at
the Exercise Price (as defined below), as adjusted from time to time as provided herein, on or before July 29, 2021 (the “Expiration
Date”), all subject to the following terms and conditions. This Warrant is being issued pursuant to that certain Placement
Agency Agreement dated June 27, 2016 between the Company and Aegis Capital Corp. (the “Placement Agency Agreement”)
and in connection with the Company’s private offering to accredited investors of its securities in accordance with, and
subject to, the terms and conditions described in that certain Confidential Private Placement Memorandum, dated June 27, 2016,
as the same may be amended and supplemented from time to time (the “Private Placement Memorandum”). Unless
otherwise defined in this Warrant, terms appearing in initial capitalized form shall have the meaning ascribed to them in the
Private Placement Memorandum.

 

    	 	1	 

     

    

 

As
used in this Warrant, (i) “Business Day” means any day other than Saturday, Sunday or any other day on which
commercial banks in the City of New York, New York, are authorized or required by law or executive order to close; (ii) “Common
Stock” means the common stock of the Company, par value $0.0001 per share, including any securities issued or issuable
with respect thereto or into which or for which such shares may be exchanged for, or converted into, pursuant to any stock dividend,
stock split, stock combination, recapitalization, reclassification, reorganization or other similar event; (iii) “Exercise
Price” means $0.50 per share of Common Stock, subject to adjustment as provided herein; (iv) “Trading Day”
means any day on which the Common Stock is traded on the primary national or regional stock exchange on which the Common Stock
is listed, or if not so listed, the OTCQX, the OTCBB, or any other market quoted by OTC Markets Group Inc. (or any successors
to any of the foregoing), if quoted thereon, is
open for the transaction of business; and (v) “Affiliate” means any person that, directly or indirectly, through
one or more intermediaries, controls, is controlled by, or is under common control with, a person, as such terms are used and
construed in Rule 144 promulgated under the Securities Act of 1933, as amended (the “Securities Act”).

 

1.           DURATION
AND EXERCISE OF WARRANTS

 

(a)          Exercise
Period. The Holder may exercise this Warrant in whole or in part on any Business Day on or before 5:00 P.M., Eastern Time,
on the Expiration Date, at which time this Warrant shall become void and of no value.

 

(b)          Exercise
Procedures.

 

(i)          While
this Warrant remains outstanding and exercisable in accordance with Section 1(a), in addition to the manner set forth in Section
1(b)(ii) below, the Holder may exercise this Warrant in whole or in part at any time and from time to time by:

 

(A)         delivery
to the Company of a duly executed copy of the Notice of Exercise attached as Exhibit A;

 

(B)         surrender
of this Warrant to the Secretary of the Company at its principal offices or at such other office or agency as the Company may
specify in writing to the Holder; and

 

(C)         payment
of the then-applicable Exercise Price per share multiplied by the number of Warrant Shares being purchased upon exercise of the
Warrant (such amount, the “Aggregate Exercise Price”) made in the form of cash, or by certified check, bank
draft or money order payable in lawful money of the United States of America or in the form of a Cashless Exercise to the extent
permitted in Section 1(b)(ii) below.

 

    	 	2	 

     

    

 

(ii)
At any time, the Holder may, in its sole discretion, exercise all or any part of the Warrant in a “cashless” or
“net-issue” exercise (a “Cashless Exercise”) by delivering to the Company (1) the Notice of
Exercise and (2) the original Warrant, pursuant to which the Holder shall surrender the right to receive upon exercise of
this Warrant, a number of Warrant Shares having a value (as determined below) equal to the Aggregate Exercise Price, in which
case, the number of Warrant Shares to be issued to the Holder upon such exercise shall be calculated using the following
formula:

 

	X	=	Y * (A - B)
	 	 	A

 

	with:	X =	the number of Warrant Shares to be issued to the Holder

 

	 	Y =	the number of Warrant Shares with respect to which the Warrant is being exercised
	 	 	 
	 	A =	the fair value per share of Common Stock on the date of exercise of this Warrant
	 	 	 
	 	B =	the then-current Exercise Price of the Warrant

 

Solely
for the purposes of this paragraph, “fair value” per share of Common Stock shall mean the average Closing Price
(as defined below) per share of Common Stock for the twenty (20) trading days immediately preceding the date on which the Notice
of Exercise is deemed to have been sent to the Company. “Closing Price” means, for any date, the price determined
by the first of the following clauses that applies:  (a) if the Common Stock is then listed or quoted on the New York
Stock Exchange, the NYSE MKT, the NASDAQ Global Select Market, the NASDAQ Global Market or the NASDAQ Capital Market or any other
national securities exchange, the closing price per share of the Common Stock for such date (or the nearest preceding date) on
the primary eligible market or exchange on which the Common Stock is then listed or quoted; (b) if prices for the Common Stock
are then quoted on the OTC Bulletin Board or any tier of the OTC Markets, the closing bid price per share of the Common Stock
for such date (or the nearest preceding date) so quoted; or (c) if prices for the Common Stock are then reported in the “Pink
Sheets” published by the National Quotation Bureau Incorporated (or a similar organization or agency succeeding to its functions
of reporting prices), the most recent closing bid price per share of the Common Stock so reported. If the Common Stock is not
publicly traded as set forth above, the “fair value” per share of Common Stock shall be reasonably and in good faith
determined by the Board of Directors of the Company as of the date which the Notice of Exercise is deemed to have been sent to
the Company.

 

    	 	3	 

     

    

 

Notwithstanding
the foregoing provisions of this Section 1(b)(ii), the Holder may not make a Cashless Exercise if and to the extent that such
exercise would require the Company to issue a number of shares of Common Stock in excess of its authorized but unissued shares
of Common Stock, less all amounts of Common Stock that have been reserved for issue upon the conversion of all outstanding securities
convertible into shares of Common Stock and the exercise of all outstanding options, warrants and other rights exercisable for
shares of Common Stock. If the Company does not have the requisite number of authorized but unissued shares of Common Stock to
permit the Holder to make a Cashless Exercise, the Company shall use commercially reasonable efforts to obtain the necessary stockholder
consent to increase the authorized number of shares of Common Stock to permit such Holder to make a Cashless Exercise pursuant
to this Section 1(b)(ii).

 

(iii)
Upon the exercise of this Warrant in compliance with the provisions of this Section 1(b), and except as limited pursuant to the
last paragraph of Section 1(b)(ii), the Company shall promptly issue and cause to be delivered to the Holder a certificate for
the Warrant Shares purchased by the Holder. Each exercise of this Warrant shall be effective immediately prior to the close of
business on the date (the “Date of Exercise”) that the conditions set forth in Section 1(b) have been satisfied,
as the case may be. On the first Business Day following the date on which the Company has received each of the Notice of Exercise
and the Aggregate Exercise Price (or notice of a Cashless Exercise in accordance with Section 1(b)(ii)) (the “Exercise
Delivery Documents”), the Company shall transmit an acknowledgment of receipt of the Exercise Delivery Documents to
the Company’s transfer agent (the “Transfer Agent”) (it being understood that the term Transfer Agent
shall be deemed to include the Secretary or other officer of the Company, if the Company does not have a Transfer Agent at the
time of any exercise of this Warrant). On or before the third Business Day following the date on which the Company has received
all of the Exercise Delivery Documents (the “Share Delivery Date”), the Company shall (X) provided that the
Transfer Agent is participating in The Depository Trust Company (“DTC”) Fast Automated Securities Transfer
Program, upon the request of the Holder, credit such aggregate number of shares of Common Stock to which the Holder is entitled
pursuant to such exercise to the Holder’s or its designee’s balance account with DTC through its Deposit Withdrawal
Agent Commission system, or (Y) if the Transfer Agent is not participating in the DTC Fast Automated Securities Transfer Program,
issue and dispatch by overnight courier to the address as specified in the Notice of Exercise, a certificate, registered in the
Company’s share register in the name of the Holder or its designee, for the number of shares of Common Stock to which the
Holder is entitled pursuant to such exercise. Upon delivery of the Exercise Delivery Documents, the Holder shall be deemed for
all corporate purposes to have become the holder of record of the Warrant Shares with respect to which this Warrant has been exercised,
irrespective of the date of delivery of the certificates evidencing such Warrant Shares. If this Warrant is submitted in connection
with any exercise pursuant to Section 1(a) and the number of Warrant Shares represented by this Warrant submitted for exercise
is greater than the actual number of Warrant Shares being acquired upon such an exercise, then the Company shall as soon
as practicable and in no event later than three (3) Business Days after any exercise and at its own expense, issue a new Warrant
of like tenor representing the right to purchase the number of Warrant Shares purchasable immediately prior to such exercise under
this Warrant, less the number of Warrant Shares with respect to which this Warrant is exercised.

 

    	 	4	 

     

    

 

(iv)
If the Company shall fail for any reason or for no reason to issue to the Holder, within three (3) Business Days of receipt of
the Exercise Delivery Documents, a certificate for the number of shares of Common Stock to which the Holder is entitled and register
such shares of Common Stock on the Company’s share register or to credit the Holder’s balance account with DTC for
such number of shares of Common Stock to which the Holder is entitled upon the Holder’s exercise of this Warrant, and if
on or after such Business Day the Holder purchases (in an open market transaction or otherwise) shares of Common Stock to deliver
in satisfaction of a sale by the Holder of shares of Common Stock issuable upon such exercise that the Holder anticipated receiving
from the Company (a “Buy-In”), then the Company shall, (A) pay in cash to the Holder the amount, if any, by
which (x) the Holder’s total purchase price (including brokerage commissions, if any) for the shares of Common Stock so
purchased (the “Buy-In Amount”) plus the amount paid by the Holder to the Company as the exercise price for
the Warrant Shares exceeds (y) the amount obtained by multiplying (1) the number of Warrant Shares that the Company was required
to deliver to the Holder in connection with the exercise at issue times (2) the price at which the sell order giving rise to such
purchase obligation was executed, and (B) at the option of the Holder, either reinstate the portion of the Warrant and equivalent
number of Warrant Shares for which such exercise was not honored or deliver to the Holder the number of shares of Common Stock
that would have been issued had the Company timely complied with its exercise and delivery obligations hereunder. For example,
if the Holder purchases Common Stock having a total purchase price of $11,000 to cover a Buy-In with respect to an attempted exercise
of shares of Common Stock, and paid the Company $5,000 as the exercise price, the Holder’s cash outlay would be a total
of $16,000; and if the aggregate sales price of the shares giving rise to such Buy-In obligation was $10,000, under clause (A)
of the immediately preceding sentence the Company shall be required to pay the Holder $6,000. The Holder shall provide the Company
written notice indicating the amounts payable to the Holder in respect of the Buy-In and, upon request of the Company, evidence
of the amount of such loss. Nothing herein shall limit a Holder’s right to pursue any other remedies available to it hereunder,
at law or in equity including, without limitation, a decree of specific performance and/or injunctive relief with respect to the
Company’s failure to timely deliver certificates representing shares of Common Stock upon exercise of the Warrant as required
pursuant to the terms hereof.

 

(c)          Partial
Exercise. This Warrant shall be exercisable, either in its entirety or, from time to time, for part only of the number of
Warrant Shares referenced by this Warrant. If this Warrant is exercised in part, the Company shall issue, at its expense, a new
Warrant, in substantially the form of this Warrant, referencing such reduced number of Warrant Shares that remain subject to this
Warrant.

 

    	 	5	 

     

    

 

(d)          Disputes.
In the case of a dispute as to the determination of the Exercise Price or the arithmetic calculation of the Warrant Shares, the
Company shall promptly issue to the Holder the number of Warrant Shares that are not disputed and, provided the Company is then
subject to the reporting obligations of the Exchange Act, resolve such dispute in accordance with Section 15.

 

2.           ISSUANCE
OF WARRANT SHARES

 

(a)          The
Company covenants that all Warrant Shares will, upon issuance in accordance with the terms of this Warrant, be (i) duly authorized,
fully paid and non-assessable, and (ii) free from all liens, charges and security interests, with the exception of claims arising
through the acts or omissions of any Holder and except as arising from applicable Federal and state securities laws.

 

(b)          The
Company shall register this Warrant upon records to be maintained by the Company for that purpose in the name of the record holder
of such Warrant from time to time. The Company may deem and treat the registered Holder of this Warrant as the absolute owner
thereof for the purpose of any exercise thereof, any distribution to the Holder thereof and for all other purposes.

 

(c)          The
Company will not, by amendment of its certificate of incorporation, by-laws or through any reorganization, transfer of assets,
consolidation, merger, dissolution, issue or sale of securities or any other voluntary action, avoid or seek to avoid the observance
or performance of any of the terms to be observed or performed hereunder by the Company, but will at all times in good faith assist
in the carrying out of all the provisions of this Warrant and in the taking of all action necessary or appropriate in order to
protect the rights of the Holder to exercise this Warrant, or against impairment of such rights.

 

3.           ADJUSTMENTS
OF EXERCISE PRICE, NUMBER AND TYPE OF WARRANT SHARES

 

(a)          The
Exercise Price and the number of shares purchasable upon the exercise of this Warrant shall be subject to adjustment from time
to time upon the occurrence of certain events described in this Section 3(a); provided, that notwithstanding the provisions
of this Section 3, the Company shall not be required to make any adjustment if and to the extent that such adjustment would require
the Company to issue a number of shares of Common Stock in excess of its authorized but unissued shares of Common Stock, less
all amounts of Common Stock that have been reserved for issue upon the conversion of all outstanding securities convertible into
shares of Common Stock and the exercise of all outstanding options, warrants and other rights exercisable for shares of Common
Stock. If the Company does not have the requisite number of authorized but unissued shares of Common Stock to make any adjustment,
the Company shall use its commercially best efforts to obtain the necessary stockholder consent to increase the authorized number
of shares of Common Stock to make such an adjustment pursuant to this Section 3(a).

 

    	 	6	 

     

    

 

(i) Subdivision
or Combination of Stock. In case the Company shall at any time subdivide (whether by way of stock dividend, stock split
or otherwise) its outstanding shares of Common Stock into a greater number of shares, the Exercise Price in effect
immediately prior to such subdivision shall be proportionately reduced and the number of Warrant Shares shall be
proportionately increased, and conversely, in case the outstanding shares of Common Stock of the Company shall be combined
(whether by way of stock combination, reverse stock split or otherwise) into a smaller number of shares, the Exercise Price
in effect immediately prior to such combination shall be proportionately increased and the number of Warrant Shares shall be
proportionately decreased. The Exercise Price and the Warrant Shares, as so adjusted, shall be readjusted in the same manner
upon the happening of any successive event or events described in this Section 3(a)(i).

 

(ii) Dividends
in Stock, Property, Reclassification. If at any time, or from time to time, all of the holders of Common Stock (or any
shares of stock or other securities at the time receivable upon the exercise of this Warrant) shall have received or become
entitled to receive, without payment therefore:

 

(A)         any
shares of stock or other securities that are at any time directly or indirectly convertible into or exchangeable for Common Stock,
or any rights or options to subscribe for, purchase or otherwise acquire any of the foregoing by way of dividend or other distribution,
or

 

(B)         additional
stock or other securities or property (including cash) by way of spin-off, split-up, reclassification, combination of shares or
similar corporate rearrangement (other than shares of Common Stock issued as a stock split or adjustments in respect of which
shall be covered by the terms of Section 3(a)(i) above),

 

then and in each
such case, the Exercise Price and the number of Warrant Shares to be obtained upon exercise of this Warrant shall be adjusted
proportionately, and the Holder hereof shall, upon the exercise of this Warrant, be entitled to receive, in addition to the number
of shares of Common Stock receivable thereupon, and without payment of any additional consideration therefor, the amount of stock
and other securities and property (including cash in the cases referred to above) that such Holder would hold on the date of such
exercise had such Holder been the holder of record of such Common Stock as of the date on which holders of Common Stock received
or became entitled to receive such shares or all other additional stock and other securities and property. The Exercise Price
and the Warrant Shares, as so adjusted, shall be readjusted in the same manner upon the happening of any successive event or events
described in this Section 3(a)(ii).

 

    	 	7	 

     

    

 

(iii)
Reorganization, Reclassification, Consolidation, Merger or Sale. If any recapitalization, reclassification or reorganization
of the capital stock of the Company, or any consolidation or merger of the Company with another corporation, or the sale of all
or substantially all of its assets or other transaction shall be effected in such a way that holders of Common Stock shall be
entitled to receive stock, securities, or other assets or property (an “Organic Change”), then, as a condition
of such Organic Change, lawful and adequate provisions shall be made by the Company whereby the Holder hereof shall thereafter
have the right to purchase and receive (in lieu of the shares of the Common Stock of the Company immediately theretofore purchasable
and receivable upon the exercise of the rights represented by this Warrant) such shares of stock, securities or other assets or
property as may be issued or payable with respect to or in exchange for a number of outstanding shares of such Common Stock equal
to the number of shares of such stock immediately theretofore purchasable and receivable assuming the full exercise of the rights
represented by this Warrant. In the event of any Organic Change, appropriate provision shall be made by the Company with respect
to the rights and interests of the Holder of this Warrant to the end that the provisions hereof (including, without limitation,
provisions for adjustments of the Exercise Price and of the number of shares purchasable and receivable upon the exercise of this
Warrant) shall thereafter be applicable, in relation to any shares of stock, securities or assets thereafter deliverable upon
the exercise hereof. The Company will not effect any such consolidation, merger or sale unless, prior to the consummation thereof,
the successor corporation (if other than the Company) resulting from such consolidation or merger or the corporation purchasing
such assets shall assume by written instrument reasonably satisfactory in form and substance to the Holder executed and mailed
or delivered to the registered Holder hereof at the last address of such Holder appearing on the books of the Company, the obligation
to deliver to such Holder such shares of stock, securities or assets as, in accordance with the foregoing provisions, such Holder
may be entitled to purchase. If there
is an Organic Change, then the Company shall cause to be mailed to the Holder at its last address as it shall appear on the books
and records of the Company, at least 10 calendar days before the effective date of the Organic Change, a notice stating the date
on which such Organic Change is expected to become effective or close, and the date as of which it is expected that holders of
the Common Stock of record shall be entitled to exchange their shares for securities, cash, or other property delivered upon such
Organic Change; provided, that the failure to mail such notice or any defect therein or in the mailing thereof shall not affect
the validity of the corporate action required to be specified in such notice. The Holder is entitled to exercise this Warrant
during the 10-day period commencing on the date of such notice to the effective date of the event triggering such notice. In
any event, the successor corporation (if other than the Company) resulting from such consolidation or merger or the corporation
purchasing such assets shall be deemed to assume such obligation to deliver to such Holder such shares of stock, securities or
assets even in the absence of a written instrument assuming such obligation to the extent such assumption occurs by operation
of law.

 

    	 	8	 

     

    

 

(b)          Certificate
as to Adjustments. Upon the occurrence of each adjustment or readjustment pursuant to this Section 3, the Company at its expense
shall promptly compute such adjustment or readjustment in accordance with the terms hereof and furnish to each Holder of this
Warrant a certificate setting forth such adjustment or readjustment and showing in detail the facts upon which such adjustment
or readjustment is based. The Company shall promptly furnish or cause to be furnished to such Holder a like certificate setting
forth: (i) such adjustments and readjustments; and (ii) the number of shares and the amount, if any, of other property which at
the time would be received upon the exercise of the Warrant.

 

(c)          Certain
Events. If any event occurs as to which the other provisions of this Section 3 are not strictly applicable but the lack of
any adjustment would not fairly protect the purchase rights of the Holder under this Warrant in accordance with the basic intent
and principles of such provisions, or if strictly applicable would not fairly protect the purchase rights of the Holder under
this Warrant in accordance with the basic intent and principles of such provisions, then the Company's Board of Directors will,
in good faith, make an appropriate adjustment to protect the rights of the Holder; provided, that no such adjustment pursuant
to this Section 3(c) will increase the Exercise Price or decrease the number of Warrant Shares as otherwise determined pursuant
to this Section 3.

 

4.           TRANSFERS
AND EXCHANGES OF WARRANT AND WARRANT SHARES

 

(a)          Registration
of Transfers and Exchanges. Subject to Section 4(c), upon the Holder’s surrender of this Warrant, with a duly executed
copy of the Form of Assignment attached as Exhibit B, to the Secretary of the Company at its principal offices or at such
other office or agency as the Company may specify in writing to the Holder, the Company shall register the transfer of all or
any portion of this Warrant. Upon such registration of transfer, the Company shall issue a new Warrant, in substantially the form
of this Warrant, evidencing the acquisition rights transferred to the transferee and a new Warrant, in similar form, evidencing
the remaining acquisition rights not transferred, to the Holder requesting the transfer.

 

(b)          Warrant
Exchangeable for Different Denominations. The Holder may exchange this Warrant for a new Warrant or Warrants, in substantially
the form of this Warrant, evidencing in the aggregate the right to purchase the number of Warrant Shares which may then be purchased
hereunder, each of such new Warrants to be dated the date of such exchange and to represent the right to purchase such number
of Warrant Shares as shall be designated by the Holder. The Holder shall surrender this Warrant with duly executed instructions
regarding such re-certification of this Warrant to the Secretary of the Company at its principal offices or at such other office
or agency as the Company may specify in writing to the Holder.

 

    	 	9	 

     

    

 

(c)          Restrictions
on Transfers. This Warrant may not be transferred at any time without (i) registration under the Securities Act or (ii) an
exemption from such registration and a written opinion of legal counsel addressed to the Company that the proposed transfer of
the Warrant may be effected without registration under the Securities Act, which opinion will be in form and from counsel reasonably
satisfactory to the Company.

 

(d)          Permitted
Transfers and Assignments. Notwithstanding any provision to the contrary in this Section 4, the Holder may transfer, with
or without consideration, this Warrant or any of the Warrant Shares (or a portion thereof) to the Holder’s Affiliates (as
such term is defined under Rule 144 of the Securities Act) without obtaining the opinion from counsel that may be required by
Section 4(c)(ii), provided, that the Holder delivers to the Company and its counsel certification, documentation, and other
assurances reasonably required by the Company’s counsel to enable the Company’s counsel to render an opinion to the
Company’s Transfer Agent that such transfer does not violate applicable securities laws.

 

(e)          Permitted
Designees. Notwithstanding anything contained herein, the Company shall, upon written instructions from the Holder to be delivered
to the Company within ninety (90) calendar days following the date of the issuance of this Replacement Selling Agent Warrant,
transfer all or a portion of this Warrant to officers, directors, employees and other associated persons of the Holder and other
registered dealers, agents and finders (collectively, “Permitted Designees”). Such transfer shall be effective upon
delivery of this Warrant and the form of assignment attached hereto as Exhibit B, accompanied by an (i) investment letter in form
and substance satisfactory to the Company and (ii) such other assurances reasonably required by the Company to ensure that such
transfer does not violate applicable securities laws.

 

5.           MUTILATED
OR MISSING WARRANT CERTIFICATE

 

If
this Warrant is mutilated, lost, stolen or destroyed, upon request by the Holder, the Company will, at its expense, issue, in
exchange for and upon cancellation of the mutilated Warrant, or in substitution for the lost, stolen or destroyed Warrant, a new
Warrant, in substantially the form of this Warrant, representing the right to acquire the equivalent number of Warrant Shares;
provided, that, as a prerequisite to the issuance of a substitute Warrant, the Company may require satisfactory evidence
of loss, theft or destruction as well as an indemnity from the Holder of a lost, stolen or destroyed Warrant.

 

    	 	10	 

     

    

 

6.           PAYMENT
OF TAXES

 

The
Company will pay all transfer and stock issuance taxes attributable to the preparation, issuance and delivery of this Warrant
and the Warrant Shares (and Replacement Selling Agent Warrant) including, without limitation, all documentary and stamp taxes;
provided, however, that the Company shall not be required to pay any tax in respect of the transfer of this Warrant,
or the issuance or delivery of certificates for Warrant Shares or other securities in respect of the Warrant Shares to any person
or entity other than to the Holder.

 

7.           FRACTIONAL
WARRANT SHARES

 

No
fractional Warrant Shares shall be issued upon exercise of this Warrant. The Company, in lieu of issuing any fractional Warrant
Share, shall round up the number of Warrant Shares issuable to nearest whole share.

 

8.           NO
STOCK RIGHTS AND LEGEND

 

No
holder of this Warrant, as such, shall be entitled to vote or be deemed the holder of any other securities of the Company that
may at any time be issuable on the exercise hereof, nor shall anything contained herein be construed to confer upon the holder
of this Warrant, as such, the rights of a stockholder of the Company or the right to vote for the election of directors or upon
any matter submitted to stockholders at any meeting thereof, or give or withhold consent to any corporate action or to receive
notice of meetings or other actions affecting stockholders (except as provided herein), or to receive dividends or subscription
rights or otherwise (except as provide herein).

 

Each
certificate for Warrant Shares initially issued upon the exercise of this Warrant, and each certificate for Warrant Shares issued
to any subsequent transferee of any such certificate, shall be stamped or otherwise imprinted with a legend in substantially the
following form:

 

“THE
SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”),
OR ANY STATE SECURITIES LAWS, AND NEITHER SUCH SECURITIES NOR ANY INTEREST THEREIN MAY BE OFFERED, SOLD, PLEDGED, ASSIGNED OR
OTHERWISE TRANSFERRED UNLESS (1) A REGISTRATION STATEMENT WITH RESPECT THERETO IS EFFECTIVE UNDER THE ACT AND ANY APPLICABLE STATE
SECURITIES LAWS, OR (2) AN EXEMPTION FROM SUCH REGISTRATION EXISTS AND THE COMPANY RECEIVES AN OPINION OF COUNSEL TO THE HOLDER
OF SUCH SECURITIES, WHICH COUNSEL AND OPINION ARE REASONABLY SATISFACTORY TO THE COMPANY, THAT SUCH SECURITIES MAY BE OFFERED,
SOLD, PLEDGED, ASSIGNED OR TRANSFERRED IN THE MANNER CONTEMPLATED WITHOUT AN EFFECTIVE REGISTRATION STATEMENT UNDER THE ACT OR
APPLICABLE STATE SECURITIES LAWS.”

 

    	 	11	 

     

    

 

9.           REGISTRATION
UNDER THE SECURITIES ACT OF 1933

 

In
connection with any Organic Change in which the Company is not the surviving corporation, the Company shall cause the surviving
corporation to provide registration rights with respect to the resale of the Warrant Shares (or the warrant shares issuable upon
the exercise of the warrant that is exchanged for this Warrant at the time of the closing of such Organic Change) under the Securities
Act which are equal to any registration rights that are granted to any purchasers of securities that are sold at the time of the
Organic Change. 

 

10.          NOTICES

 

All
notices, consents, waivers, and other communications under this Warrant must be in writing and will be deemed given to a party
when (a) delivered to the appropriate address by hand or by nationally recognized overnight courier service (costs prepaid); (b)
sent by facsimile or e-mail with confirmation of transmission by the transmitting equipment; (c) received or rejected by the addressee,
if sent by certified mail, return receipt requested, if to the registered Holder hereof; or (d) seven days after the placement
of the notice into the mails (first class postage prepaid), to the Holder at the address, facsimile number, or e-mail address
furnished by the registered Holder to the Company in accordance with the Subscription Agreement by and between the Company and
the Holder, or if to the Company, to it at 1545 Route 206 South, Suite 302, Bedminster, NJ 07921, Attention: Roelof Rongen, Chief
Executive Officer (or to such other address, facsimile number, or e-mail address as the Holder or the Company as a party may designate
by notice the other party).

 

11.          SEVERABILITY

 

If
a court of competent jurisdiction holds any provision of this Warrant invalid or unenforceable, the other provisions of this Warrant
will remain in full force and effect. Any provision of this Warrant held invalid or unenforceable only in part or degree will
remain in full force and effect to the extent not held invalid or unenforceable.

 

12.          BINDING
EFFECT

 

This
Warrant shall be binding upon and inure to the sole and exclusive benefit of the Company, its successors and assigns, the registered
Holder or Holders from time to time of this Warrant and the Warrant Shares.

 

    	 	12	 

     

    

 

13.          SURVIVAL
OF RIGHTS AND DUTIES

 

This
Warrant shall terminate and be of no further force and effect on the earlier of 5:00 P.M., Eastern Time, on the Expiration Date
or the date on which this Warrant has been exercised in full.

 

    	 	13	 

     

    

 

14.         GOVERNING
LAW

 

This
Warrant will be governed by and construed under the laws of the State of New York without regard to conflicts of laws principles
that would require the application of any other law.

 

15.         DISPUTE
RESOLUTION

 

In
the case of a dispute as to the determination of the Exercise Price or the arithmetic calculation of the Warrant Shares, the Company
shall submit the disputed determinations or arithmetic calculations via facsimile within two Business Days of receipt of the Notice
of Exercise giving rise to such dispute, as the case may be, to the Holder. If the Holder and the Company are unable to agree
upon such determination or calculation of the Exercise Price or the Warrant Shares within three Business Days of such disputed
determination or arithmetic calculation being submitted to the Holder, and provided that the Company is then subject to the reporting
obligations of the Exchange Act, then the Company shall, within two Business Days, submit via facsimile (a) the disputed determination
of the Exercise Price to an independent, reputable investment bank selected by the Company and approved by the Holder or (b) the
disputed arithmetic calculation of the Warrant Shares to the Company’s independent, outside accountant. The Company shall
cause at its expense the investment bank or the accountant, as the case may be, to perform the determinations or calculations
and notify the Company and the Holder of the results no later than ten (10) Business Days from the time it receives the disputed
determinations or calculations. Such investment bank’s or accountant’s determination or calculation, as the case may
be, shall be binding upon all parties absent demonstrable error.

 

16.         NOTICES
OF RECORD DATE

 

Upon
(a) any establishment by the Company of a record date of the holders of any class of securities for the purpose of determining
the holders thereof who are entitled to receive any dividend or other distribution, or right or option to acquire securities of
the Company, or any other right, or (b) any capital reorganization, reclassification, recapitalization, merger or consolidation
of the Company with or into any other corporation, any transfer of all or substantially all the assets of the Company, or any
voluntary or involuntary dissolution, liquidation or winding up of the Company, or the sale, in a single transaction, of a majority
of the Company’s voting stock (whether newly issued, or from treasury, or previously issued and then outstanding, or any
combination thereof), the Company shall mail to the Holder at least ten (10) Business Days, or such longer period as may be required
by law, prior to the record date specified therein, a notice specifying (i) the date established as the record date for the purpose
of such dividend, distribution, option or right and a description of such dividend, option or right, (ii) the date on which any
such reorganization, reclassification, transfer, consolidation, merger, dissolution, liquidation or winding up, or sale is expected
to become effective and (iii) the date, if any, fixed as to when the holders of record of Common Stock shall be entitled to exchange
their shares of Common Stock for securities or other property deliverable upon such reorganization, reclassification, transfer,
consolation, merger, dissolution, liquidation or winding up.

 

    	 	14	 

     

    

 

17.         RESERVATION
OF SHARES

 

The
Company shall reserve and keep available out of its authorized but unissued shares of Common Stock for issuance upon the exercise
of this Warrant, free from pre-emptive rights, such number of shares of Common Stock for which this Warrant shall from time to
time be exercisable. The Company will take all such reasonable action as may be necessary to assure that such Warrant Shares may
be issued as provided herein without violation of any applicable law or regulation. Without limiting the generality of the foregoing,
the Company covenants that it will use commercially reasonable efforts to take all such action as may be necessary or appropriate
in order that the Company may validly and legally issue fully paid and nonassessable Warrant Shares upon the exercise of this
Warrant and use commercially reasonable efforts to obtain all such authorizations, exemptions or consents, including but not limited
to consents from the Company’s stockholders or Board of Directors or any public regulatory body, as may be necessary to
enable the Company to perform its obligations under this Warrant.

 

18.         NO
THIRD PARTY RIGHTS

 

This
Warrant is not intended, and will not be construed, to create any rights in any parties other than the Company and the Holder,
and no person or entity may assert any rights as third-party beneficiary hereunder.

 

[SIGNATURE PAGE
FOLLOWS]

 

    	 	15	 

     

    

 

IN
WITNESS WHEREOF, the Company has caused this Warrant to be duly executed as of the date first set forth above.

 

	 	MATINAS BIOPHARMA HOLDINGS, INC.
	 	 	 
	 	By:	 
	 	Name:    Roelof Rongen
	 	Title:     Chief Executive
    Officer

 

    	 	16	 

     

    

 

EXHIBIT A

 

NOTICE OF EXERCISE

 

(To be executed
by the Holder of Warrant if such Holder desires to exercise Warrant)

 

To Matinas BioPharma
Holdings, Inc.:

 

The
undersigned hereby irrevocably elects to exercise this Warrant and to purchase thereunder, ___________________ full shares of
Matinas BioPharma Holdings, Inc. Common Stock issuable upon exercise of the Warrant and delivery of:

 

(1)         $_________
(in cash as provided for in the foregoing Warrant) and any applicable taxes payable by the undersigned pursuant to such Warrant;
and

 

(2)         a
Warrant for __________ shares of Common Stock (pursuant to a Cashless Exercise in accordance with Section 1(b)(ii) of the Warrant)
(check here if the undersigned desires to deliver a Warrant for an unspecified number of shares equal to the number sufficient
to effect a Cashless Exercise [___]).

 

The
undersigned requests that certificates for such shares be issued in the name of:

 

_________________________________________

(Please print name,
address and social security or federal employer

identification number
(if applicable))

 

_________________________________________

 

_________________________________________

 

If
the shares issuable upon this exercise of the Warrant are not all of the Warrant Shares which the Holder is entitled to acquire
upon the exercise of the Warrant, the undersigned requests that a new Warrant evidencing the rights not so exercised be issued
in the name of and delivered to:

 

_________________________________________

(Please print name,
address and social security or federal employer

identification number
(if applicable))

 

_________________________________________

 

_________________________________________

 

	 	Name of Holder (print):    ________________________
	 	(Signature):  ___________________________________
	 	(By:) _________________________________________
	 	(Title:) ________________________________________
	 	Dated:  ________________________________________

 

    	 	17	 

     

    

 

EXHIBIT B

 

FORM OF ASSIGNMENT

 

FOR
VALUE RECEIVED, ___________________________________ hereby sells, assigns and transfers to each assignee set forth below all of
the rights of the undersigned under the Warrant (as defined in and evidenced by the attached Warrant) to acquire the number of
Warrant Shares set opposite the name of such assignee below and in and to the foregoing Warrant with respect to said acquisition
rights and the shares issuable upon exercise of the Warrant:

 

	Name of Assignee	 	Address	 	Number of Shares
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 

 

If
the total of the Warrant Shares are not all of the Warrant Shares evidenced by the foregoing Warrant, the undersigned requests
that a new Warrant evidencing the right to acquire the Warrant Shares not so assigned be issued in the name of and delivered to
the undersigned.

 

	 	Name of Holder (print):   ________________________
	 	(Signature):  ___________________________________
	 	(By:) _________________________________________
	 	(Title:) ________________________________________
	 	Dated:  ________________________________________

 

    	 	18

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00263-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00263-of-00352.parquet"}]]